<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00045370</url>
  </required_header>
  <id_info>
    <org_study_id>02-023</org_study_id>
    <secondary_id>CDR0000256468</secondary_id>
    <secondary_id>NCI-G02-2104</secondary_id>
    <secondary_id>W-AR-3066K1-124-US</secondary_id>
    <secondary_id>WYETH-C-C0125-32</secondary_id>
    <nct_id>NCT00045370</nct_id>
  </id_info>
  <brief_title>Chemotherapy and Biological Therapy in Treating Patients With Locally Advanced or Metastatic Kidney Cancer</brief_title>
  <official_title>A Phase I Study of the Safety, Tolerability, and Antitumor Activity of Escalating Doses of Intravenous CCI-779 Given in Combination With Escalating Doses of Interferon-Alpha to Patients With Advanced Renal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Biological therapies such as interferon alfa use different ways to&#xD;
      stimulate the immune system and stop cancer cells from growing. Combining biological therapy&#xD;
      with chemotherapy may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of combining chemotherapy with biological&#xD;
      therapy in treating patients who have locally advanced or metastatic kidney cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of CCI-779 in combination with interferon alfa in&#xD;
           patients with locally advanced or metastatic renal cell cancer.&#xD;
&#xD;
        -  Determine the safety and tolerability of this regimen in these patients.&#xD;
&#xD;
        -  Determine, preliminarily, any antitumor activity of this regimen in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation, multicenter study.&#xD;
&#xD;
      Patients receive interferon alfa (IFN-A) subcutaneously 3 times a week. Beginning on week 2,&#xD;
      patients also receive CCI-779 IV over 30 minutes once weekly. Treatment continues in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of at least 6 patients receive escalating doses of CCI-779 and then IFN-A until the&#xD;
      maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at&#xD;
      which at least 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined,&#xD;
      20 additional patients are treated at that dose level.&#xD;
&#xD;
      Patients are followed at 30 days.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 50 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2002</start_date>
  <completion_date type="Actual">November 2003</completion_date>
  <primary_completion_date type="Actual">November 2003</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Kidney Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interferon alfa</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temsirolimus</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed locally advanced or metastatic renal cell cancer&#xD;
&#xD;
               -  Progressive disease after treatment with 0-2 courses of immunotherapy,&#xD;
                  chemotherapy, or other systemic therapy for advanced disease&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  No concurrent CNS metastases&#xD;
&#xD;
               -  Prior CNS metastases allowed if no residual disease by MRI&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 9 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  AST and ALT no greater than 3 times upper limit of normal (ULN) (5 times ULN if liver&#xD;
             metastases present)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine less than 2 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No unstable angina&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Cholesterol no greater than 350 mg/dL&#xD;
&#xD;
          -  Triglycerides no greater than 400 mg/dL&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Not immunocompromised&#xD;
&#xD;
          -  No active autoimmune disorder&#xD;
&#xD;
          -  No active infection requiring antibiotic therapy&#xD;
&#xD;
          -  No other serious concurrent illness&#xD;
&#xD;
          -  No known hypersensitivity to components of CCI-779, interferon alfa, diphenhydramine&#xD;
             hydrochloride, or both acetaminophen and nonsteroidal anti- inflammatory drugs&#xD;
&#xD;
          -  No other major illness that would preclude study participation&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after study&#xD;
             participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks since prior immunotherapy&#xD;
&#xD;
          -  No prior interferon alfa&#xD;
&#xD;
          -  No other concurrent immunotherapy&#xD;
&#xD;
          -  No prophylactic growth factors&#xD;
&#xD;
          -  Concurrent epoetin alfa allowed&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy&#xD;
&#xD;
          -  No prior CCI-779&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent hormonal therapy for malignancy (megestrol for appetite loss allowed)&#xD;
&#xD;
          -  Concurrent inhaled or replacement steroids allowed&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  At least 3 weeks since prior surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks since prior immunosuppressive agents&#xD;
&#xD;
          -  At least 4 weeks since prior investigational agents&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No concurrent immunosuppressive therapy&#xD;
&#xD;
          -  No concurrent anticonvulsants known to be cytochrome P450 inducers, ketoconazole,&#xD;
             diltiazem, rifampin, terfenadine, cisapride, astemizole, or pimozide&#xD;
&#xD;
          -  No concurrent maintenance therapy for life-threatening ventricular arrhythmia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert J. Motzer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>September 6, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 4, 2013</last_update_submitted>
  <last_update_submitted_qc>June 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 5, 2013</last_update_posted>
  <keyword>recurrent renal cell cancer</keyword>
  <keyword>stage III renal cell cancer</keyword>
  <keyword>stage IV renal cell cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

